Crewe Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Crewe Advisors's VRTX Position: Q3 2026 in Review
Crewe Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 9.6% in Q3 2026, selling an estimated $27.6K and leaving 509 shares worth $266K. The position accounts for 0.02% of the portfolio, ranked #188.
Crewe Advisors first reported a position in VRTX in Q3 2020 and has held it in 19 quarters since. The position peaked at $280K in Q2 2026. 1,798 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Crewe Advisors held 509 shares of Vertex Pharmaceuticals worth $266K as of Q3 2026.
- Crewe Advisors sold 54 Vertex Pharmaceuticals shares in Q3 2026, an estimated $27.6K.
- Vertex Pharmaceuticals made up 0.02% of Crewe Advisors's portfolio in Q3 2026, its #188 holding.
- Crewe Advisors first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 19 quarters since.
- Crewe Advisors's Vertex Pharmaceuticals position peaked at $280K in Q2 2026.
- 1,798 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Crewe Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.